This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric/GEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic.
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Adequate liver, renal, pulmonary, and cardiac function.
Adequate hematologic function.
Has received cytotoxic chemotherapy, biologic anticancer agents, checkpoint inhibitors, or radiation therapy (excluding bone-only radiation therapy) ≤3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NRM-823
History of Grade 2 pneumonitis requiring steroids or any Grade 3 or 4 pneumonitis from any prior therapy.
Has received an investigational therapy <4 weeks or 5 half-lives prior to the first dose of NRM823, whichever is shorter prior to the first dose of NRM-823.
With the exception of alopecia and Grade ≤2 neuropathy, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study drug.
Single group
NRM-823
DrugNRM-823 is a bispecific T-Cell Engager
Incidence of treatment-emergent adverse events (TEAE)
Number of participants who experience treatment emergent AEs or SAEs
Incidence of dose-limiting toxicities (DLTs)
Number of participants who experience a DLT. A DLTs include protocol defined adverse events.
Click on the lead sponsor to view all of their trials.
